AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00297401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: QD, PO, up to 8 weeks
Study NCT01267578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccination
Description: Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
Study NCT02630030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study NCT00941343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin (XATRAL® - SL770499)
Description: One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
Study NCT01584934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Description: Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
Study NCT01584934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
Study NCT01091610 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: purely observational retrospective study. no interventions are planned.
Study NCT01643213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Boston Scientific SCS Trial Therapy
Description: No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
Study NCT01643213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSC approved SCS Trial Therapy w/ OMG
Description: No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
Study NCT04130841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Limiting Membrane Peeling
Description: After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
Study NCT04130841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Limiting Membrane Peeling
Description: After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
Study NCT02353780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)
Description: TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
Study NCT02353780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept; SQ; specifics to be determined by the treating rheumatologist.
Study NCT02353780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab; SQ; specifics determined by the treating rheumatologist.
Study NCT00513214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
Study NCT00513214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
Study NCT04199520 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surgery combined with systemic therapy
Description: surgery combined with systemic therapy
Study NCT04199520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy
Description: systemic therapy
Study NCT02600260 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enoxaparin
Description: Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
Study NCT02600260 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Hospitalized patients that score less than three are not prescribed enoxaparin.
Study NCT01731548 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hyperfractionated radiation therapy for both arms
Description: 1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
Study NCT01731548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiation therapy for both arms
Description: 1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
Study NCT00058591 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection of EBV specific CTLS
Description: The dose levels for this study are as follows:~Level Dose~1. 2 x 107 CTLs/m2~2. 5 x 107 CTLs/m2~3. 1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals.
Study NCT03795948 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PROMs
Description: Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses.
Study NCT00990886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 12 weeks
Study NCT00990886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride
Description: 15 mg once daily for 12 weeks
Study NCT04560842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A high flow oxygen device.
Description: The HFNC group use high flow oxygen device for 48 hours
Study NCT04560842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional oxygen therapy
Description: Conventional oxygen device
Study NCT03702699 — intervention group
Intervention type: DEVICE
Intervention: Auricular point detector
Description: This device is only for auricular detection. No additional intervention will be delivered.
Study NCT02835066 — intervention group
Intervention type: OTHER
Intervention: Integrated Fitness Assessment
Description: Undergo function/fitness assessment
Study NCT02835066 — intervention group
Intervention type: PROCEDURE
Intervention: Psychosocial Assessment and Care
Description: Undergo psychosocial health assessments
Study NCT02835066 — intervention group
Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
Study NCT02638532 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Foot Fat Pad Grafting
Description: Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
Study NCT02062697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lavage of the Cavum uteri and proximal fallopian tubes
Study NCT02062697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liquid-PAP smear
Study NCT01207960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
Study NCT02094040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive municipality-based follow-up visit
Description: Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
Study NCT00229801 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: MRI
Study NCT04254757 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two different treatment
Description: One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
Study NCT00632294 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue Sample
Description: A leftover sample of the removed allograft bone will be collected.
Study NCT01163617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current syringe
Description: Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
Study NCT01163617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis syringe
Description: Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
Study NCT01163617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in current autoinjector
Description: Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
Study NCT01163617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adalimumab delivered in Physiolis autoinjector
Description: Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
Study NCT01250938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESI - Community Outreach
Description: This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
Study NCT04626076 — intervention group
Intervention type: OTHER
Intervention: Comparative Observational Cohort Study
Description: This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
Study NCT03739892 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard stroke rehabilitation
Description: standard rehabilitation according to the french standard care and to the severity of the patient
Study NCT03965364 — intervention group
Intervention type: DEVICE
Intervention: INCRAFT
Description: Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
Study NCT03972540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful eating intervention
Description: A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
Study NCT02066116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinect-based rehabilitation plus occupational therapy
Description: The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
Study NCT02066116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham virtual rehabilitation education plus occupational therapy
Description: For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
Study NCT02349880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: shared decision making training
Study NCT02349880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shared decision making training
Study NCT01267032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care
Description: A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
Study NCT01267032 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Integrated Care
Description: A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
Study NCT01267032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment for Insomnia
Description: A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
Study NCT01267032 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Desensitization Treatment for Insomnia
Description: A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
Study NCT00437762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A Injection
Description: Botulinum Toxin A Injection
Study NCT00437762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo Injection
Study NCT02873663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma and head hair collection
Description: Plasma and head hair collection
Study NCT02428400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG1050
Description: TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
Study NCT02428400 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: adenovirus reference material (ARM) buffer
Study NCT01769586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Study NCT01769586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT04236778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VE303
Description: The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
Study NCT04236778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
Study NCT04236778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Vancomycin
Description: Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
Study NCT00583544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TC-2216
Description: Multiple ascending dose groups will be explored.
Study NCT00583544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-2216
Description: Multiple ascending dose groups will be explored.
Study NCT05604950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Since the data were collected retrospectively, there were no interventions
Description: Since the data were collected retrospectively, there were no interventions
Study NCT00658619 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 400 µg Brimonidine Tartrate Implant
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
Study NCT00658619 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 200 µg Brimonidine Tartrate Implant
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
Study NCT00658619 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham (no implant)
Description: Sham in one or both eyes on Day 1 and Month 6.
Study NCT00658619 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (no implant)
Description: Sham in one or both eyes on Day 1 and Month 6.
Study NCT00677222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMI MultiStem®
Description: AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
Study NCT04877600 — intervention group
Intervention type: OTHER
Intervention: dual task performance
Description: dual task performance measurement
Study NCT02164617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program (WSEB)
Description: Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
Study NCT01603160 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality Improvement
Description: There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized.
Study NCT04015063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Aging Skin Care product
Description: Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
Study NCT02936999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
Study NCT00776256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta-glucan and fructooligosaccharide
Description: 1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Study NCT00776256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beta-glucan and fructooligosaccharide
Description: 1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2